Capecitabine-Enhanced Brachytherapy in Locally Advanced Cervical Cancer: A Phase II Non-Randomized Trial on Safety and Efficacy
In conclusion, while capecitabine-augmented brachytherapy was demonstrated to be safe in patients with advanced cervical cancer, its addition did not yield significant improvements in DFS or OS.
Authors
- Sare Hosseini (ORCID: https://orcid.org/0000-0002-1242-763X)
- I Nyoman Yusha Tresnatama Giri (ORCID: https://orcid.org/0009-0003-6979-3838)
- Seyed Alireza Javadinia (ORCID: https://orcid.org/0000-0003-2467-837X)
- Soudeh Arastouei (ORCID: https://orcid.org/0000-0002-1087-9982)
- Fatemeh Homaei Shandiz (ORCID: https://orcid.org/0000-0002-7718-5387)
- Habibollah Esmaily (ORCID: https://orcid.org/0000-0003-4139-546X)
- Mahdiye Dayanni
- Maliheh Hasanzadeh Mofard
Institutions
- Mashhad University of Medical Sciences (IR)
- Purdue University West Lafayette (US)
- Imam Reza Hospital (IR)
- Sabzevar University of Medical Sciences (IR)
Publication Details
- Journal
- Cancer Investigation
- Published
- 2025-04-21
- DOI
- https://doi.org/10.1080/07357907.2025.2493238
- Citations
- 3
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.17
Funders
- Mashhad University of Medical Sciences